Intangible Assets, net (Narrative) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended					9 Months Ended
	Sep. 30, 2014 drug_application	Sep. 30, 2013	Sep. 30, 2014 product drug_application	Sep. 30, 2013 product	Sep. 30, 2014 Sky Growth Merger [Member] Developed products [Member]	Sep. 30, 2014 Sky Growth Merger [Member] Subsequently Developed In Process Research and Development [Member]	Nov. 06, 2012 Watson/Actavis Divestiture Products [Member] drug_application product	Sep. 30, 2014 Watson/Actavis Divestiture Products [Member]	Sep. 30, 2014 JHP Group Holdings [Member] product annual_IPRD_group	Sep. 30, 2014 JHP Group Holdings [Member] Developed products [Member]	Sep. 30, 2014 JHP Group Holdings [Member] Trade Names [Member]
Intangible Assets, Net (Excluding Goodwill) [Line Items]
Amortization expense			$ 121,348	$ 135,744
Proceeds from the sale of ANDA	3,800		750	0
Number of ANDAs sold	3		3
Weighted average amortization period					5 years	6 years		5 years		9 years	5 years
Number of generic products with marketing rights acquired through merger (products)							5
Number of abbreviated new drug applications awaiting regulatory approval (drug applications)							8
Number of IPR&D groups created									6
Intangible asset impairment	$ 11,466	$ 39,480	$ 89,086	$ 39,946
Number of discontinued products									1
Number of products impaired not expected to achieve forecasted operating results			8	5